<DOC>
	<DOCNO>NCT01792934</DOCNO>
	<brief_summary>The purpose study compare overall survival rate colorectal cancer patient multi-organ metastasis indication first line systemic treatment randomize treatment combination chemotherapy treatment combination chemotherapy additional maximal tumor debulking include surgical tumor resection , RFA , ( DEBIRI- ) TACE SBRT , depend best clinical judgement accord standardized treatment algorithm . Our hypothesis maximal tumor debulking addition systemic treatment chemotherapy biologicals provide improvement progression free overall survival patient group .</brief_summary>
	<brief_title>Chemotherapy Maximal Tumor Debulking Multi-organ Colorectal Cancer Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histological cytological documentation cancer require . Indication first line palliative systemic treatment metastatic colorectal cancer ( mCRC ) . Patients CRC metastasis ( primary tumor exclude metastatic site ) ≥ 2 different organ least &gt; 1 extrahepatic metastasis ≥ 2 different organ include &gt; 5 hepatic metastasis locate one lobe ≥ 2 different organ include either positive paraaortal lymph node celiac lymph node adrenal metastasis pleural carcinomatosis peritoneal carcinomatosis Feasible radical tumor debulking . Incomplete tumor debulking allow least 80 % metastasis treat . To meet inclusion criterion cytological analysis perform case uncertainty presence lesion e.g . false positive false negative result image . Age ≥ 18 year . WHO performance status 0 1 . Life expectancy least 12 week . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin ≥ 5.6 mmol/L ; Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; Platelet count ≥ 100*109/l ; Total bilirubin ≤ 1.5 time upper limit normal ; ALT AST ≤ 2.5 x upper limit normal ( ≤ 5 x upper limit normal subject liver involvement cancer ) ; Albumin &gt; 30 g/l ; Serum creatinine ≤ 1.5 x upper limit normal MDRD ≥ 50 ml/min ; Prothrombin time INR &lt; 1.5 x ULN , unless coumarin derivates use . Due interaction capecitabine , patient use coumarin derivates treat LMWH instead . Activated partial thromboplastin time &lt; 1.25 x ULN ( therapeutic anticoagulation therapy allow treatment interrupt judge treat physician ) . Written informed consent . Prior ( neo ) adjuvant chemotherapy &lt; 6 month last treatment first detection extrahepatic metastasis , except neoadjuvant capecitabine context chemoradiation rectal carcinoma . Candidates HIPEC . Patients liver metastasis Evidence brain metastasis . History prior malignancy except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Patients malignancy eligible remain disease free least 5 year . History cardiac disease : Congestive heart failure &gt; NYHA class 2 ; Active Coronary Artery Disease ( define myocardial infarction within 6 month prior screen ) ; Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) . Uncontrolled hypertension . Blood pressure must ≤160/95 mm Hg time screen stable antihypertensive regimen . Blood pressure must stable least 3 separate measurement least 2 separate day . Uncontrolled infection ( &gt; grade 2 NCICTC version 4.0 ) . Pregnant breastfeed woman . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must agree use adequate barrier birth control measure ( e.g. , cervical cap , condom , diaphragm ) intrauterine device course trial . Oral birth control method alone consider adequate study , potential pharmacokinetic interaction study drug oral contraceptive . Concomitant use oral barrier contraceptive advise . Concurrent anticancer chemotherapy , immunotherapy investigational drug therapy study within 4 week start study drug . Concomitant use dexamethasone , anticonvulsant antiarrhythmic drug digoxin beta blocker . Severe allergy contrast medium control premedication . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result . Any condition unstable could jeopardize safety subject compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>